The class of drugs, called PARP inhibitors, fights against tumors with a specific mutation in the MRE11 gene. Approximately 15 percent of colorectal cancers have microsatellite instability, which is an error in the DNA. A large majority of these tumors have the MRE11 gene mutation, suggesting a broader application of PARP inhibitors.
Researchers found PARP inhibitors were even more effective when there are two copies of the MRE11 gene mutation. They are planning to launch a phase 1 clinical trial to test the utility of PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11.
Read the U-M Health release about PARP inhibitors in colorectal cancer.
Related articles on colorectal cancer:
Office Desk Jobs Double Colon Cancer Risk
Local Washington Health Board Reverses Approval of Colonoscopy Campaign
Coverage of Preventive Services Under New Healthcare Law Causing Confusion
